Investors need to pay close attention to AZN stock based on the movements in the options market late

https://youtu.be/H_RititNE8U

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZen

The logic of a pharma megamerger is questionable, but AstraZeneca's record isn't.

180 Wealth Advisors LLC purchased a new stake in Astrazeneca Plc (NYSE: AZN) in the second quarter,

There are "no discussions" ongoing between AstraZeneca and ​Bristol Myers Squibb over a potential ‌d

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASD

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASD

SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and d

BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today ann

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in

Holz framed the logic bluntly. “If you take these two companies and you slash expenses, that would b

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYS

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation

Falling Oil Please click here for an enlarged chart of United States Oil ETF (NYSE:USO). N

Bristol-Myers Squibb (BMY) stock is declining this morning, reversing its premarket gains as Wall St

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a co

Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an openin

Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the worl

Jim Cramer senses a 'fake out' in the rumored $400B AstraZeneca and Bristol Myers Squibb meg

Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in t

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Monda

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

BMY and AZN reportedly talk of a merger, stocks rebound as jobs print approaches, and more

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in t

Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share.

AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks on

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datr

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighe

U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index

Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Com

AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sa

Results in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s c

AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $2.63 per share which beat the analyst conse

https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-plus-pertuzumab-recommended-for-approval-in-the

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary

U.S. stock futures mixed, Dow down 0.1%. Levi Strauss shares down 6.1%, Noah Holdings down 14%, Ioni

Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Helix, the leading enterprise genomics company, today announced a multi-year relationship with Astra

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Abbisko and AstraZeneca will jointly develop a Phase 1/2 NSCLC therapy combining lumipodlin with Tag

AstraZeneca reported positive HPP trial data while Enhertu gained EU approval for HER2-positive soli

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datrow

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Major FDA wins for AstraZeneca: Truqap combination approved for advanced prostate cancer; Ultomiris